Abstract
Commun epithelial ovarian carcinoma, in particular stage III and IV (FIGO) have a poor prognosis with a survival rate < 20 % at 5 years. Paradoxically ovarian cancer is very responsive to chemotherapy with high overall response rates demonstrated consistently using Cisplatin based combination regimens. It is this contrast of high response rates with major reductions in tumor burden, yet low numbers of durable complete remissions, that let us to use a high-dose chemotherapy and ABMT in poor risk patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag France
About this paper
Cite this paper
Legros, A. et al. (1994). High-dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT) in 39 advanced ovarian cancers: long-term results. In: Banzet, P., Holland, J.F., Khayat, D., Weil, M. (eds) Cancer Treatment An Update. Springer, Paris. https://doi.org/10.1007/978-2-8178-0765-2_98
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0765-2_98
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0767-6
Online ISBN: 978-2-8178-0765-2
eBook Packages: Springer Book Archive